Published April 19, 2012
Dow Jones Newswires
ZURICH – Novartis AG (NVS) said Thursday the development program of an experimental drug for the treatment of Hepatitis C has been placed on hold by U.S. regulators after the death of a patient, which may be linked the drug.
A small number of patients treated with the DEB025 drug or alisporivir developed pancreatitis, which is believed to be a contributing factor to the death, Novartis said.
The Swiss drug maker said the Food and Drug Administration has placed the development program of DEB025 on hold. It added the death was the first and only case in the overall DEB025 program, which involved about 1800 patients to date.
No comments:
Post a Comment